{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T22:49:43Z","timestamp":1689893383871},"reference-count":42,"publisher":"Georg Thieme Verlag KG","issue":"11","funder":[{"name":"home institutions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Clin Endocrinol Diabetes"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n                    Background The presence of chronic kidney disease (CKD) influences the\n                    type of antiglycaemic therapy and the risk for hypoglycaemia.<\/jats:p><jats:p>\n                    Methods In 2006, 2011 and 2016 health insurance data of people with\n                    diabetes type 2 were screened for CKD and the presence of severe hypoglycaemia\n                    (sHypo). The type of antihyperglycaemic therapy was recorded due to Anatomical\n                    Therapeutic Chemical (ATC) codes up to 3 months before suffering sHypo.<\/jats:p><jats:p>\n                    Results The prevalence of CKD increased from 5.3% in 2006 to\n                    7.3% in 2011 and 11.2% in 2016. Insulin-based therapies were\n                    used in 39.0, 39.1, and 37.9% of patients with, but only in 17.7, 17.4,\n                    and 18.8% of patients without CKD. Although the proportion of the CKD\n                    stages 1, 2 and 5 decreased, CKD stages 3 and 4 increased. The proportion of\n                    sHypo in CKD declined from 2006 (3.5%) to 2011 (3.0%) and 2016\n                    (2.2%) but was still more than 10 times higher as compared to type 2\n                    diabetic patients without CKD (0.3\/0.2\/0.2%) conferring\n                    a significantly higher probability of sHypo (OR 9.30, 95%CI\n                    9.07\u20139.54) in CKD. The probability of sHypo was significantly lower in\n                    2016 than in 2006 both in patients with (OR 0.58; CI 0.55\u20130.61) and\n                    without CKD (OR 0.70; CI 0.68\u20130.73).<\/jats:p><jats:p>\n                    Conclusion The prevalence of CKD increased from 2006 to 2016. Patients\n                    with CKD exhibited a 9-fold increased probability of sHypo, especially in\n                    patients treated with insulin plus oral anti-diabetic drugs. However, the rate\n                    and risk for sHypo decreased over time, probably as a consequence of new\n                    antidiabetic treatment options, better awareness of sHypo, and changed therapy\n                    goals.<\/jats:p>","DOI":"10.1055\/a-1129-6699","type":"journal-article","created":{"date-parts":[[2020,4,14]],"date-time":"2020-04-14T23:03:11Z","timestamp":1586905391000},"page":"821-830","source":"Crossref","is-referenced-by-count":4,"title":["Antidiabetic Therapy and Rate of Severe Hypoglycaemia in Patients\n                    with Type 2 Diabetes and Chronic Kidney Disease of Different Stages \u2013 A\n                    Follow-up Analysis of Health Insurance Data from Germany"],"prefix":"10.1055","volume":"129","author":[{"given":"Martin","family":"Busch","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, University Hospital Jena, Jena,\n                    Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Lehmann","sequence":"additional","affiliation":[{"name":"Center for Clinical Studies, University Hospital Jena, Jena,\n                    Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunter","family":"Wolf","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, University Hospital Jena, Jena,\n                    Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"G\u00fcnster","sequence":"additional","affiliation":[{"name":"Research Institute of the Local Health Care Funds, Berlin,\n                    Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich Alfons","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, University Hospital Jena, Jena,\n                    Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolle","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, University Hospital Jena, Jena,\n                    Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2020,4,14]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of\n                    type 2 diabetes (UKPDS 35): Prospective observational study","volume":"321","author":"I M Stratton","year":"2000","journal-title":"BMJ"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with\n                    conventional treatment and risk of complications in patients with type 2\n                    diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression\n                    of long-term complications in insulin-dependent diabetes mellitus. The Diabetes\n                    Control and Complications Trial Research Group","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0140-6736(09)60697-8","article-title":"Effect of intensive control of glucose on cardiovascular outcomes and death in\n                    patients with diabetes mellitus: A meta-analysis of randomised controlled\n                    trials","volume":"373","author":"K K Ray","year":"2009","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1053\/j.ajkd.2014.08.001","article-title":"Diabetic kidney disease: A report from an ADA Consensus Conference","volume":"64","author":"K R Tuttle","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/dme.13397","article-title":"Increase in the incidence of severe hypoglycaemia in people with Type 2 diabetes\n                    in spite of new drugs: Analysis based on health insurance data from Germany","volume":"34","author":"N Muller","year":"2017","journal-title":"Diabet Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00125-014-3460-0","article-title":"Management of hyperglycaemia in type 2 diabetes, 2015: A patient-centred\n                    approach. Update to a position statement of the American Diabetes Association\n                    and the European Association for the Study of Diabetes","volume":"58","author":"S E Inzucchi","year":"2015","journal-title":"Diabetologia"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/jgs.12381","article-title":"Age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment\n                    in type 2 diabetes mellitus: Findings from the Renal Insufficiency and\n                    Cardiovascular Events Italian Multicenter Study","volume":"61","author":"A Solini","year":"2013","journal-title":"J Am Geriatr Soc"},{"key":"ref9","first-page":"367","article-title":"Discrepancies among consensus documents, guidelines, clinical practice and the\n                    legal framework for the treatment of type 2 diabetes mellitus patients","volume":"32","author":"C del Pozo-Fernandez","year":"2012","journal-title":"Nefrologia"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/ndt\/gfu294","article-title":"Disease burden and risk profile in referred patients with moderate chronic\n                    kidney disease: composition of the German Chronic Kidney Disease (GCKD)\n                    cohort","volume":"30","author":"S Titze","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1093\/ndt\/gfr456","article-title":"The German Chronic Kidney Disease (GCKD) study: Design and methods","volume":"27","author":"K U Eckardt","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12882-016-0273-z","article-title":"Glycaemic control and antidiabetic therapy in patients with diabetes mellitus\n                    and chronic kidney disease - cross-sectional data from the German Chronic Kidney\n                    Disease (GCKD) cohort","volume":"17","author":"M Busch","year":"2016","journal-title":"BMC Nephrol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1001\/archinternmed.2011.537","article-title":"Association between glycemic control and adverse outcomes in people with\n                    diabetes mellitus and chronic kidney disease: A population-based cohort\n                    study","volume":"171","author":"S Shurraw","year":"2011","journal-title":"Arch Intern Med"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/dme.12747","article-title":"Healthcare utilization of people with type 2 diabetes in Germany: An analysis\n                    based on health insurance data","volume":"32","author":"N Muller","year":"2015","journal-title":"Diabet Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.diabres.2014.12.007","article-title":"Trends in the prescription of antidiabetic medications from 2009 to 2012 in a\n                    general practice of Southern Italy: A population-based study","volume":"108","author":"C Rafaniello","year":"2015","journal-title":"Diabetes Res Clin Pract"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.clinthera.2007.02.012","article-title":"Antidiabetic prescriptions and glycemic control in German patients with type 2\n                    diabetes mellitus: A retrospective database study","volume":"29","author":"N Yurgin","year":"2007","journal-title":"Clin Ther"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.2337\/dc12-1759","article-title":"Quality of care of people with type 2 diabetes in eight European countries:\n                    Findings from the Guideline Adherence to Enhance Care (GUIDANCE) study","volume":"36","author":"M A Stone","year":"2013","journal-title":"Diabetes Care"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"ii121","DOI":"10.1093\/ndt\/gfw330","article-title":"The ascending rank of chronic kidney disease in the global burden of disease\n                    study","volume":"32","author":"K J Jager","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1001\/jama.298.17.2038","article-title":"Prevalence of chronic kidney disease in the United States","volume":"298","author":"J Coresh","year":"2007","journal-title":"JAMA"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jcjd.2017.06.008","article-title":"Managing the course of kidney disease in adults with type 2 diabetes: From the\n                    old to the new","volume":"42","author":"R M Goldenberg","year":"2018","journal-title":"Can J Diabetes"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2165\/00129784-200707050-00002","article-title":"Defining the role of repaglinide in the management of type 2 diabetes mellitus:\n                    A review","volume":"7","author":"O E Johansen","year":"2007","journal-title":"Am J Cardiovasc Drugs"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0140-6736(07)61514-1","article-title":"Congestive heart failure and cardiovascular death in patients with prediabetes\n                    and type 2 diabetes given thiazolidinediones: A meta-analysis of randomised\n                    clinical trials","volume":"370","author":"R M Lago","year":"2007","journal-title":"Lancet"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/ki.1992.125","article-title":"Relationships among natriuresis, atrial natriuretic peptide and insulin in\n                    insulin-dependent diabetes","volume":"41","author":"P Fioretto","year":"1992","journal-title":"Kidney Int"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1016\/S0140-6736(14)61402-1","article-title":"Heart failure in diabetes: Effects of anti-hyperglycaemic drug therapy","volume":"385","author":"R E Gilbert","year":"2015","journal-title":"Lancet"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2337\/dc14-1958","article-title":"Liraglutide promotes natriuresis but does not increase circulating levels of\n                    atrial natriuretic peptide in hypertensive subjects with type 2 diabetes","volume":"38","author":"J A Lovshin","year":"2015","journal-title":"Diabetes Care"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"S P Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"S P Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"JF E Mann","year":"2017","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"B Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"C Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"B Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1056\/NEJMoa1003795","article-title":"Severe hypoglycemia and risks of vascular events and death","volume":"363","author":"S Zoungas","year":"2010","journal-title":"N Engl J Med"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.2215\/CJN.00800209","article-title":"Frequency of hypoglycemia and its significance in chronic kidney disease","volume":"4","author":"M F Moen","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"b5444","DOI":"10.1136\/bmj.b5444","article-title":"The effects of baseline characteristics, glycaemia treatment approach, and\n                    glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc\n                    epidemiological analysis of the ACCORD study","volume":"340","author":"M E Miller","year":"2010","journal-title":"BMJ"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.0894-0959.2004.17346.x","article-title":"Use of insulin and oral hypoglycemic medications in patients with diabetes\n                    mellitus and advanced kidney disease","volume":"17","author":"R W Snyder","year":"2004","journal-title":"Semin Dial"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.diabres.2017.07.033","article-title":"Renal glucose metabolism in normal physiological conditions and in diabetes","volume":"133","author":"M Alsahli","year":"2017","journal-title":"Diabetes Res Clin Pract"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1093\/ndt\/gfq649","article-title":"Impaired renal function modifies the risk of severe hypoglycaemia among users of\n                    insulin but not glyburide: A population-based nested case-control study","volume":"26","author":"M A Weir","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1055\/s-0035-1569380","article-title":"High quality of diabetes care based upon individualised treatment goals - A\n                    cross sectional study in 4784 patients in Germany","volume":"124","author":"C Kloos","year":"2016","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"ref41","first-page":"CD011798","article-title":"Insulin and glucose-lowering agents for treating people with diabetes and\n                    chronic kidney disease","volume":"9","author":"C Lo","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1093\/ndt\/gfx219","article-title":"The diabetes pandemic suggests unmet needs for \u2018CKD with\n                    diabetes\u2019 in addition to \u2018diabetic\n                    nephropathy\u2019-implications for pre-clinical research and drug\n                    testing","volume":"33","author":"L Anguiano Gomez","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1007\/s00125-018-4729-5","article-title":"Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the\n                    American Diabetes Association (ADA) and the European Association for the Study\n                    of Diabetes (EASD)","volume":"61","author":"M J Davies","year":"2018","journal-title":"Diabetologia"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"ehz486.","DOI":"10.1093\/eurheartj\/ehz486,[Epub ahead of print]","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases\n                    developed in collaboration with the EASD","volume":"31","author":"F Cosentino","year":"2019","journal-title":"Eur Heart J"}],"container-title":["Experimental and Clinical Endocrinology &amp; Diabetes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1129-6699.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T23:07:25Z","timestamp":1635548845000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1129-6699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,14]]},"references-count":42,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,10,29]]},"published-print":{"date-parts":[[2021,11]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1129-6699","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0947-7349","1439-3646"],"issn-type":[{"value":"0947-7349","type":"print"},{"value":"1439-3646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,14]]}}}